Dysmenorrhea Treatment Market - Overview
Dysmenorrhea refers to the painful menstruation women experience during their monthly discharging periods. While it is normal for women to have mild abdominal cramps on the initial days of their menstruation, about 30% of women experience severe pain along with headaches and nausea that could be termed as Dysmenorrhea. Over the past decade, the prevalence of Dysmenorrhea is observed to be growing. Reasons could be environmental changes, change in diet, and lack of nutritious diet, etc.
Acknowledging the exponential growth the market perceives currently; Market Research Future (MRFR), in its recently published market forecast asserts that the global Dysmenorrhea Treatment Market will reach USD 8.40 Bn. by 2023, registering a striking CAGR of 12.28% throughout the forecast period (2017 – 2023). In 2016, the market had valued at USD 5.68 Bn.
MRFR recognizes the following companies as the key players in the global dysmenorrhea treatment market— Johnson Johnson (US), GlaxoSmithKline PLC (UK), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Focus Consumer Healthcare, LLC (US), Novartis AG (Switzerland), Pfizer, Inc. (US), Reckitt Benckiser Group plc. (UK), Sanofi S.A. (France) and Viatris Inc. (US) among others.
Dysmenorrhea Treatment Market - Segmentations
MRFR has segmented the report into three key dynamics for an easy grasp and enhanced understanding: -
By Type : Primary and Secondary (Adenomyosis, Endometriosis, Uterine myomas, Cervical stenosis, Endometrial polyps, and Obstructive malformations of genital tract.).
By Treatment: Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Hormonal, and Combined Oral Contraceptive among others.
By End-User: Hospitals, Clinics, Diagnostic Centers, and Pharmaceutical Companies among Others.
By Regions: North America, Europe, APAC and Rest of the World.
Global Dysmenorrhea Treatment Market - Regional Analysis
Globally North America leads the primary dysmenorrhea causes with the significant market share. The Market is expected to grow phenomenally from 2017 to 2023. Attributing to the favorable reimbursement scenario and higher expenditure on healthcare the market is expected to perceive a healthy growth.
The factor contributing to the market growth include increasing prevalence of issues and disorders associated with women’s reproductive system fuelled by the changing lifestyle and growing awareness towards the availability of the treatments. The US, backed by the technological advances and availability of funding for the development of new therapeutics and treatment accounts for the major contributor to the market growth.
Europe emerging as a lucrative market for Dysmenorrhea Treatment will expand registering a phenomenal CAGR. The resurging economy in the region is expected to foster the regional market growth, increasing per capita healthcare expenditures. The financial support provided by private and governments bodies for RD activities and new improved reimbursement policies in healthcare will fuel the Dysmenorrhea Treatment market in Europe.
Global Dysmenorrhea Treatment Market - Competitive Landscape
The competitive market for Dysmenorrhea Treatment is fragmented with many large and small players operating in the market. Market players incorporate acquisition, collaboration, expansion, technology launch and strategic partnership. These players substantially invest in RD and clinical trials to develop effective drugs.
To help accelerate pharmaceutical innovations and to gain a better understanding of the conditions, these pharma companies collaborate with academia and the biotech industry partners who can contribute cutting-edge technologies and specialized knowledge.
These collaborations are one of the innovation strategies of market players. Companies can leverage the latest scientific knowledge and translate it into innovative medicines through partnering. These partnerships can kindle the innovative impulses that advance medicine and benefit patients as well as partners.
Industry/Innovation/ Related News:
January 04, 2018 – Pfizer Inc. (US) a pharmaceutical conglomerate announced the partnership with 23andMe (US), a privately held personal genomics and biotechnology company to aid understanding of depression, dysmenorrhea and the genetic heterogeneity of lupus and inflammatory bowel disease. Pfizer believes that such collaborations will help it to potentially usher in a new era of patient care defined by targeted research methods and ultimately better patient outcomes.
About US:
Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
